Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC grew its stake in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 25.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 34,844 shares of the biotechnology company’s stock after buying an additional 7,138 shares during the period. SG Americas Securities LLC’s holdings in Anavex Life Sciences were worth $374,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of AVXL. Prairiewood Capital LLC purchased a new stake in shares of Anavex Life Sciences in the fourth quarter valued at $223,000. Carnegie Investment Counsel grew its position in Anavex Life Sciences by 4.7% during the fourth quarter. Carnegie Investment Counsel now owns 76,778 shares of the biotechnology company’s stock valued at $825,000 after acquiring an additional 3,445 shares during the period. SeaCrest Wealth Management LLC acquired a new position in shares of Anavex Life Sciences during the fourth quarter worth about $164,000. Fiduciary Alliance LLC acquired a new position in shares of Anavex Life Sciences during the fourth quarter worth about $119,000. Finally, Watts Gwilliam & Co. LLC acquired a new position in shares of Anavex Life Sciences during the fourth quarter worth about $279,000. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Price Performance

AVXL opened at $8.64 on Tuesday. Anavex Life Sciences Corp. has a 1-year low of $3.25 and a 1-year high of $14.44. The business has a 50 day moving average price of $9.98 and a two-hundred day moving average price of $7.59. The company has a market capitalization of $732.84 million, a price-to-earnings ratio of -16.62 and a beta of 0.69.

Anavex Life Sciences (NASDAQ:AVXL) last released its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. Equities analysts expect that Anavex Life Sciences Corp. will post -0.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on AVXL. HC Wainwright reiterated a “buy” rating and issued a $42.00 price target on shares of Anavex Life Sciences in a research note on Tuesday, January 28th. D. Boral Capital reaffirmed a “buy” rating and set a $46.00 target price on shares of Anavex Life Sciences in a report on Tuesday, January 28th.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.